ANAPC11

Across TCGA pan-cancer cohorts, ANAPC11 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANAPC11 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher ANAPC11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANAPC11 expression acts as an unfavorable survival marker.

SKCM, LGG, and LIHC are the cancer types where ANAPC11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.087	0.739	<.001	36	view →
LGG	DFS	Median	All	0.172	0.845	<.001	9	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ANAPC11–SKCM (DFS)

Open the SKCM breakdown →